Rockefeller Capital Management L.P. Raises Stake in Viking Therapeutics, Inc. $VKTX

Rockefeller Capital Management L.P. boosted its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 38.6% in the 4th quarter, HoldingsChannel reports. The fund owned 53,053 shares of the biotechnology company’s stock after acquiring an additional 14,772 shares during the period. Rockefeller Capital Management L.P.’s holdings in Viking Therapeutics were worth $1,866,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Royal Fund Management LLC purchased a new position in Viking Therapeutics in the fourth quarter valued at $1,518,000. Rafferty Asset Management LLC raised its stake in Viking Therapeutics by 26.6% in the third quarter. Rafferty Asset Management LLC now owns 199,387 shares of the biotechnology company’s stock valued at $5,240,000 after buying an additional 41,888 shares in the last quarter. Baker BROS. Advisors LP purchased a new stake in Viking Therapeutics during the 3rd quarter worth about $9,621,000. WINTON GROUP Ltd purchased a new stake in Viking Therapeutics during the 3rd quarter worth about $1,805,000. Finally, Meadowbrook Wealth Management LLC acquired a new position in shares of Viking Therapeutics during the 4th quarter worth about $1,309,000. 76.03% of the stock is owned by hedge funds and other institutional investors.

Viking Therapeutics Price Performance

NASDAQ VKTX opened at $39.01 on Wednesday. The company has a fifty day moving average of $31.75 and a two-hundred day moving average of $32.65. The company has a market capitalization of $4.53 billion, a PE ratio of -9.42 and a beta of 0.69. Viking Therapeutics, Inc. has a 1 year low of $22.96 and a 1 year high of $43.15.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.36). During the same period last year, the business posted ($0.41) earnings per share. On average, research analysts expect that Viking Therapeutics, Inc. will post -4.7 earnings per share for the current year.

Analyst Ratings Changes

VKTX has been the topic of a number of recent analyst reports. Morgan Stanley set a $95.00 price objective on Viking Therapeutics in a report on Thursday, April 30th. Truist Financial began coverage on Viking Therapeutics in a report on Wednesday, May 27th. They issued a “buy” rating and a $83.00 price target for the company. Cantor Fitzgerald dropped their price target on shares of Viking Therapeutics from $105.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Viking Therapeutics in a report on Monday, April 20th. Finally, BTIG Research restated a “buy” rating and set a $125.00 price objective on shares of Viking Therapeutics in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $93.60.

Viking Therapeutics Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non?alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor?beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.